3TC30mg+NVP50mg+AZT60mg Dispersible Tablets - Revolutionary HIV-1 Treatment
ProcurenetShort description
The 3TC30mg + NVP50mg + AZT60mg Dispersible Tablets are crucial in HIV-1 management, especially beneficial for adults and children. These tablets are a blend of 30mg Lamivudine (3TC), 50mg Nevirapine (NVP), and 60mg Zidovudine (AZT), operating as Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
- Product Form: Dispersible tablets for hassle-free administration.
- Ingredients: Consist of 3TC (30mg), NVP (50mg), and AZT (60mg).
- Longevity: A 2-years shelf life facilitating long-term HIV-1 management.
- Packaging: Encased in a securely packed bottle to ensure protection against light and moisture.
-
Procurenet Team Tshim Sha Tsui
Hong Kong
3 years
Description
The 3TC30mg+NVP50mg+AZT60mg Dispersible Tablets are a revolutionary antiretroviral medication meticulously designed to battle HIV-1 infection. A potent blend of three active ingredients - Lamivudine 30mg, Nevirapine 50mg, and Zidovudine 60mg, the tablets are expertly engineered to provide a robust treatment for HIV in adults and children.
These power-packed tablets offer novel benefits:
- Blend of three active agents - Lamivudine, Nevirapine, and Zidovudine - known for their anti-HIV properties.
- 60 tablets per pack for consistent, uninterrupted treatment, bolstering treatment success.
- Impedes the action of nucleoside reverse transcriptase, blockading HIV replication and controlling its spread.
- Conveniently dispersible in water, allowing easy ingestion for those unable to tolerate solid medication.
- Clear dosage guidelines dictated by patient weight and age, eliminating potential errors and ensuring ideal treatment outcomes.
This breakthrough in HIV-1 management therapy, the 3TC30mg+NVP50mg+AZT60mg Dispersible Tablets ceaselessly work to inhibit viral replication, offering hope for a brighter, healthier future to both adult and pediatric patients infected with the virus.
The tablets easily disperse in water, ensuring patients' comfort and ease of ingestion, even for those who struggle with swallowing solid medications. The well-defined dosage system leaves no room for error, fostering successful, ongoing treatment without gaps or overdosing issues.
The tablets should be stored at a temperature below 30°C (86°F) in a tightly sealed container, away from light. The medicine should be kept away from children. A two-week lead-in therapy with Nevirapine is not advised due to potential complications. Regulatory details can be found on the WHO prequalification program and USFDA websites.
With the 3TC30mg+NVP50mg+AZT60mg Dispersible Tablets, you will have access to a transformative solution in HIV-1 management. The combination of convenience, efficacy, and precision in dosage amounts to a product that is unmatched in its field, delivering a potent medication regimen for HIV-1 patients.
